Tulane Home Tulane Shield logo linking to site home page

Myeloma Clinical Trials

EAA173
Duratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETERSMM)
More Information

 

SWOG S1803
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MMM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
More Information